Tobacco is the leading modifiable cause of cardiovascular disease, cancer, and respiratory diseases and is thus a serious global public health problem. In 2006, Uruguay implemented the World Health Organization Framework Convention on Tobacco Control (WHO-FCTC) and achieved a decrease in the smoking rate and improvements in cardiovascular and respiratory health. We analyzed the clinical and economic impacts of tobacco control measures on the healthcare costs for acute myocardial infarction, which was reduced by 17%. The costs avoided for other diseases were not included. The study examined the trend in a healthcare institution and projected the result to the country's population. The cost analysis used the diagnosis-related groups (DRG) methodology, combined with the institution's accounting reports. Besides the hospitalization costs, the analysis included patient transportation, invasive cardiovascular procedures, and healthcare costs for the 12 months following the acute myocardial infarction. The cost per patient was USD 12,037. Considering a decrease of 500 acute myocardial infarctions per year, the estimated annual savings are USD 6 million in medical care costs for the averted acute myocardial infarctions, besides savings from averted work absenteeism, subsequent disability, and disability adjusted life years. This successful tobacco control policy has been the leading public health intervention in the last 30 years in Uruguay. The study aims to contribute to the guidelines determined by the World Health Organization (WHO).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/0102-311X00149019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Prognostic Implications of Non-Culprit Lesions in Patients Presenting With an Acute Myocardial Infarction: Is It the Angiographic Stenosis Severity or the Underlying High-Risk Morphology?
Circulation
January 2025
Department of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China (J.D., J.Z., X.X., Y.C., S.S., S.L., L.C., Y.W., L.L., R.G., D.H., X.M., R.Z., H.Y., T.C., J.T., X.L., S.J., J.H., C.F.B.Y.).
Background: Patients with acute myocardial infarction and angiographically obstructive non-culprit lesions are at high risk for recurrent major adverse cardiac events (MACEs). However, it remains largely unknown whether events are due to stenosis severity or due to the underlying high-risk lesion morphology.
Methods: Between January 2017 and December 2021, 1312 patients with acute myocardial infarction underwent optical coherence tomography of all the 3 main epicardial arteries after successful percutaneous coronary intervention.
Coronary Myocardial Bridge Updates: Anatomy, Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Options.
Tex Heart Inst J
January 2025
Center for Women's Heart and Vascular Health, The Texas Heart Institute, Houston, Texas.
Myocardial bridging is a frequent anomaly of the heart in humans and other animals. A myocardial bridge is typically characterized by the systolic narrowing seen with traditional catheter angiography, but this abnormality is not by itself a sign of ischemia or the need for intervention. In particular, transient spontaneous angina must be corroborated by reproducible narrowing during acetylcholine testing; this narrowing occurs during resting conditions and is responsive to nitroglycerin administration.
View Article and Find Full Text PDFCan a mechanical circulatory support comprehensive approach to cardiogenic shock at referral centers reduce 30-day mortality?
Front Cardiovasc Med
January 2025
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Although mortality risk prediction in cardiogenic shock (CS) is possible, assessing the impact of the multitude of therapeutic efforts on outcomes is not straightforward. We assessed whether a temporary mechanical circulatory support comprehensive approach to the treatment of CS may reduce 30-day mortality as compared to expected mortality predicted by the recently proposed Cardiogenic Shock Score (CSS). Consecutive CS patients supported by pVAD Impella (Abiomed, Danvers, MA) at two national referral centers were included.
View Article and Find Full Text PDFManagement and Outcomes of Type I and Type II Myocardial Infarction in Cardiogenic Shock.
CJC Open
February 2024
CAPITAL Research Group, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Background: Type I myocardial infarction (T1MI) or type II myocardial infarction (T2MI) have different underlying mechanisms; however, in the setting of cardiogenic shock (CS), it is not understood if patients experience resultantly different outcomes. The objective of this study was to determine clinical features, biomarker patterns, and outcomes in these subgroups.
Methods: Patients from the CAPITAL-DOREMI trial presenting with acute myocardial infarction-associated CS (n = 103) were classified as T1MI (n = 61) or T2MI (n = 42).
Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort study.
BMJ Oncol
September 2023
Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK.
Objective: Although adjuvant trastuzumab-based treatment (TBT) improves survival for patients with HER2-positive early invasive breast cancer (EIBC), risk of toxicity grows as patient age increases. We examined use of TBT and associated severe acute toxicity event (SATE) rates to understand the real-world impact.
Methods And Analysis: Women (50+ years), newly diagnosed with HER2-positive EIBC in England, 2014-2019, were identified from Cancer Registry data, linked to the Systemic Anti-Cancer Therapy dataset for TBT information.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!